CA2699301A1 - Produit de dispersion solide de medicaments de type n-aryle a base d'uree - Google Patents

Produit de dispersion solide de medicaments de type n-aryle a base d'uree Download PDF

Info

Publication number
CA2699301A1
CA2699301A1 CA2699301A CA2699301A CA2699301A1 CA 2699301 A1 CA2699301 A1 CA 2699301A1 CA 2699301 A CA2699301 A CA 2699301A CA 2699301 A CA2699301 A CA 2699301A CA 2699301 A1 CA2699301 A1 CA 2699301A1
Authority
CA
Canada
Prior art keywords
group
phenyl
amino
alkyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2699301A
Other languages
English (en)
Inventor
Rudolf Schroeder
Tanja Heitermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2699301A1 publication Critical patent/CA2699301A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2699301A 2007-10-19 2008-10-17 Produit de dispersion solide de medicaments de type n-aryle a base d'uree Abandoned CA2699301A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19
US60/999,618 2007-10-19
PCT/EP2008/064076 WO2009050291A2 (fr) 2007-10-19 2008-10-17 Produit de dispersion solide de médicaments de type n-aryle à base d'urée

Publications (1)

Publication Number Publication Date
CA2699301A1 true CA2699301A1 (fr) 2009-04-23

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699301A Abandoned CA2699301A1 (fr) 2007-10-19 2008-10-17 Produit de dispersion solide de medicaments de type n-aryle a base d'uree

Country Status (18)

Country Link
EP (1) EP2197425A2 (fr)
JP (1) JP2011500649A (fr)
KR (1) KR20100087170A (fr)
CN (1) CN101827584A (fr)
AU (1) AU2008313622A1 (fr)
BR (1) BRPI0818340A2 (fr)
CA (1) CA2699301A1 (fr)
CO (1) CO6270206A2 (fr)
CR (1) CR11442A (fr)
DO (1) DOP2010000117A (fr)
EC (1) ECSP10010183A (fr)
GT (1) GT201000102A (fr)
MX (1) MX2010004291A (fr)
PA (1) PA8800101A1 (fr)
RU (1) RU2010119929A (fr)
UA (1) UA100865C2 (fr)
WO (1) WO2009050291A2 (fr)
ZA (1) ZA201002095B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
MX2012014387A (es) * 2010-06-09 2013-05-01 Abbvie Inc Dispersiones solidas que contienen inhibidores de cinasa.
CN103917236A (zh) 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
LT2782557T (lt) 2011-11-23 2018-12-27 Array Biopharma, Inc. Farmacinės kompozicijos
WO2014003678A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil
WO2014003677A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant des particules de dispersion solide contenant du tadalafil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959926A1 (fr) * 2005-10-25 2008-08-27 Abbott Laboratories Preparation comprenant un medicament faiblement soluble dans l'eau et son procede d'utilisation
WO2007066189A2 (fr) * 2005-12-09 2007-06-14 Pfizer Products Inc. Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree
CA2667720A1 (fr) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Forme de dosage pharmaceutique pour l'administration orale d'un inhibiteur de la tyrosine kinase

Also Published As

Publication number Publication date
CO6270206A2 (es) 2011-04-20
WO2009050291A2 (fr) 2009-04-23
PA8800101A1 (es) 2009-05-15
GT201000102A (es) 2012-03-12
JP2011500649A (ja) 2011-01-06
UA100865C2 (ru) 2013-02-11
ECSP10010183A (es) 2010-06-29
AU2008313622A1 (en) 2009-04-23
DOP2010000117A (es) 2010-05-15
ZA201002095B (en) 2011-11-30
EP2197425A2 (fr) 2010-06-23
RU2010119929A (ru) 2011-11-27
CN101827584A (zh) 2010-09-08
CR11442A (es) 2010-09-06
BRPI0818340A2 (pt) 2015-04-22
KR20100087170A (ko) 2010-08-03
MX2010004291A (es) 2010-08-02
WO2009050291A3 (fr) 2010-04-08

Similar Documents

Publication Publication Date Title
CA2699301A1 (fr) Produit de dispersion solide de medicaments de type n-aryle a base d'uree
EP1003487B1 (fr) Formulation pharmaceutique avec liberation controlee de substances actives
US20090143423A1 (en) Solid dispersion product containing n-aryl urea-based compound
ITMI991402A1 (it) Composti amorfi e relative composizioni farmaceutiche
KR100522239B1 (ko) 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
WO2023195953A1 (fr) Comprimé pelliculé comprenant du selexi̇pag
KR20230034207A (ko) 경구용 의약 조성물 및 그 제조 방법
JP2001511796A (ja) 環状四級アンモニウム化合物を経口投与するための乾燥形態の薬学的調合剤
JP2003527424A (ja) オキサゾリジノン錠剤製剤
CN107072954B (zh) 用于口服给药的包含洛贝格列酮的药物组合物
WO2020122244A1 (fr) Comprimé, et procédé de fabrication de celui-ci
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
WO2021006267A1 (fr) Sel de dérivé de pyrazole et préparation de dérivé de pyrazole
JP5106119B2 (ja) シクロオキシゲナーゼ−2阻害剤を含む経口投与用の薬剤、およびその調製方法
JP2024091760A (ja) 非晶質固体分散体を含む複合物
CA3232832A1 (fr) Composition pharmaceutique et son procede de preparation
RU2261095C1 (ru) Лекарственная форма, обладающая нестероидным противовоспалительным действием, и способ ее изготовления
JP2021066715A (ja) イミダフェナシンを含む粒子の製造方法及びその利用
CN116898808A (zh) 一种FXIa的药物组合物及其制备方法与医药用途
TR2021009380A2 (tr) Amorf dapagliflozi̇n ve metformi̇n hi̇droklorür i̇çeren tablet formülasyonlari i̇çi̇n bi̇r proses
TR201605993A1 (tr) Gastroi̇ntesti̇nal hastaliklarin tedavi̇si̇nde kullanilan farmasöti̇k formülasyonlar
FR2913018A1 (fr) Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
JP2011063567A (ja) 保存安定性の向上した錠剤

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20141017